Category: Uncategorized
during the COVID-19 pandemic – and these benefits are why they will likely become an industry standard in the near future.
Latin America is heavily represented in cancer diagnosis statistics, but critically underrepresented in oncology clinical trials.
AstaZeneca is joining a growing body of pharmaceutical development companies to realize the multifaceted value of decentralized, at-home medical trials.
Clinical trial management is a hot topic in the wake of COVID-19. As many study sponsors and CROs pivot to decentralized clinical trial (DCT) modalities, the industry gets smarter. This is because meeting trial participants at home addresses many previous study challenges. This is amplified in Latin America. The obvious benefits are boosting trial enrollment […]
Opportunities to highlight the importance of clinical research trends in Latin America are rare. That’s why it’s big news when a podcast that focuses on the journey of medical technical (medtech) leadership invites H Clinical to participate in a conversation on the state of clinical trials in Latin America. Mitchell Parrish, president of H Clinical, […]
More patients worldwide participate in clinical trials from home. According to an article from Applied Clinical Trials, decentralized clinical trials are the reason why. As the COVID-19 pandemic began to impact study conduct in 2020, the need to adopt decentralized trial models was hastened to keep research moving forward. Logistics and Infrastructure But unlike most […]
The leading provider of in-home trial support in Latin America completes consolidation of affiliates in Argentina, Brazil, Colombia, Mexico, Peru, and Panama. (PR Newswire: TAMPA, Fla., August 11, 2021) – H Clinical has completed consolidation of decentralized clinical trial (DCT) and in-home visit operations in Latin America. This delivers streamlined support and a single, centralized […]
As research study sponsors and CROs look to reach clinical trial recruitment and participant retention goals, they should consider moving some trial site activities into patients’ homes. This was proven during the COVID-19 pandemic, as the use of decentralized and hybrid trials became the norm by necessity. According to the data in this article published […]
Life sciences organizations are paying closer attention to ways that improve the patient experience in clinical research trials, while also increasing trial participant enrollment and retention. According to an article by McKinsey & Company that says COVID-19 catalyzed a shift to decentralized clinical trials, typically 70% of potential trial participants live more than two hours […]
A report from Global Data was cited in a Fierce Biotech article that claims more than a quarter of rare disease trials are culled due to low patient rates. The data analytics and life science consultancy firm examined over 700 rare disease studies from 2016 to 2020 to arrive at the conclusion. How to Better […]